Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

RBC Capital analyst Brian Abrahams, on Feb. 20, maintained Vertex Pharmaceuticals with a Sector Perform rating and raised the price target from $407 to $408.

Shannon Saccocia of NB Private Wealth named iShares U.S. Financials ETF (NYSE:IYF) as her final trade.

Don't forget to check out our premarket coverage here

Joshua Brown of Ritholtz Wealth Management picked Netflix, Inc. (NASDAQ:NFLX), saying the stock is close to its 52-week high.

Supporting his view, MoffettNathanson analyst Michael Nathanson, on March 17, upgraded Netflix from Neutral to Buy and raised the price target from $850 to $1100.

Price Action:

• Vertex Pharmaceuticals shares gained 0.5% to close at $502.55 on Thursday.
• iShares U.S. Financials ETF fell 0.6% during Thursday's session.
• Netflix shares gained 0.6% to close at $976.72 on Thursday.

Check This Out:

• Jim Cramer: Stryker Is A ‘Good’ Company, Says He Likes This Utilities Stock

Photo: Shutterstock